Table 3 Accumulated dose volume histograms (DVH) over the entire breathing cycle for PTV and WCS optimized plans based on prescription by coverage according to ICRU 91
PTVITV(i) | PTVVH(ii) | WCSCITV(iii) | WCSGTV(iv) | |||
|---|---|---|---|---|---|---|
Motion effect (Wilcoxon’s) | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | Mean ± SD (range) | (i) vs.(ii) vs.(iii) vs.(iv) p-value < 0.05 | |
GTV | ||||||
D98 (Gy) | 61.5 ± 1.8 (56.3–63.0) | 59.7 ± 1.6 (56.5–62.5) | 59.0 ± 1.8 (55.5–62.0) | 57.2 ± 1.9 (55.1–61.3) | (i)-(iii); (i)-(iv); (ii)-(iv) | |
p-value | 0.003 | 1.000 | 0.022 | 0.092 | ||
D50 (Gy) | 65.7 ± 2.2 (59.6–67.9) | 62.8 ± 2.1 (59.8–65.6 | 63.2 ± 2.2 (59.7–67.2) | 60.3 ± 2.2 (56.1–65.0) | (i)-(iv) | |
p-value | 0.581 | 0.092 | 0.022 | 0.267 | ||
D2 (Gy) | 69.1 ± 2.3 (64.5–73.3) | 65.2 ± 3.0 (61.1–70.1) | 66.9 ± 3.6 (61.5–72.4) | 64.0 ± 2.8 (60.5–70.3) | (i)-(iv) | |
p-value | < 0.01 | < 0.01 | < 0.01 | < 0.01 | ||
Chest Wall | ||||||
V30Gy (cm3) | 28.5 ± 18.7 (6.3–72.4) | 20.0 ± 10.6 (1.1–41.6) | 16.9 ± 9.0 (1.7–31.4) | 13.0 ± 8.4 (1.0–32.5) | (i)-(iii); (i)-(iv); (ii)-(iv); (iii)-(iv); | |
p-value | 0.20 | 0.02 | < 0.01 | < 0.01 | ||
Lung | ||||||
V5Gy (cm3) | 16.5 ± 5.8 (7.7–30.0) | 17.3 ± 5.1 (8.0–26.7) | 16.8 ± 5.7 (7.5–28.7) | 16.1 ± 5.6 (7.2–28.3) | (ii)-(iv) | |
p-value | 0.14 | 0.17 | 0.20 | 0.03 | ||
V20Gy (cm3) | 8.3 ± 3.8 (3.6–15.4) | 7.8 ± 3.3 (3.6–13.8) | 7.7 ± 3.7 (3.3–15.1) | 7.0 ± 3.4 (2.8–13.4) | (i)-(iii); (i)-(iv); (ii)-(iv); (iii)-(iv) | |
p-value | 0.27 | 0.11 | 0.25 | 0.10 | ||
MLD (Gy) | 4.0 ± 1.6 (1.8–7.2) | 4.1 ± 1.3 (1.9–6.1) | 3.9 ± 1.4 (1.8–6.3) | 3.8 ± 1.4 (1.7–6.3) | (i)-(iv); (ii)-(iv) | |
p-value | 0.06 | 0.38 | 0.22 | 0.18 | ||